皮肤黑色素瘤辅助治疗新选择
本综述汇总了已切除III/IV期黑色素瘤辅助治疗的临床试验数据。抗PD-1单药和BRAF/MEK抑制剂是III期患者的标准治疗,可改善无复发生存;已切除IV期患者中纳武利尤单抗是唯一获批药物,伊匹木单抗联合纳武利尤单抗的II期结果令人鼓舞。优化治疗仍需预后/预测生物标志物及降低毒性、克服耐药的策略。
要点
- III期黑色素瘤术后标准辅助治疗为抗PD-1单药或BRAF/MEK抑制剂。
- IIIB期(AJCCv7)纳武利尤单抗2年/3年无复发生存约72%/65%。
- 已切除IV期黑色素瘤仅纳武利尤单抗获批,双免疫联合II期结果有前景。
核心结论
- 已切除高危黑色素瘤的随机研究显示,免疫治疗或靶向治疗较安慰剂/伊匹木单抗改善无复发生存。
- 优化治疗需要预后和预测生物标志物,以及降低治疗相关毒性和克服耐药的策略。
研究设计与样本
- 本综述概述了最新临床试验数据、当前辅助治疗格局及其临床应用和早期黑色素瘤管理的预期进展。
主要发现
- 对于IIIB期(AJCCv7)黑色素瘤,纳武利尤单抗2年和3年无复发生存分别约为72%和65%,帕博利珠单抗为70%和65.7%,达拉非尼/曲美替尼为68%和60%。
- 对于IIIC期(AJCCv7)黑色素瘤,纳武利尤单抗2年和3年无复发生存分别为60%和53.5%,帕博利珠单抗为60%和54.3%,达拉非尼/曲美替尼为59%和47%。
- 已切除IV期黑色素瘤中纳武利尤单抗是唯一获批药物,近期II期临床试验显示伊匹木单抗联合纳武利尤单抗也有 promising 疗效。
- 确定哪种治疗对总生存影响最大需要长期数据。
- 选择辅助治疗时,方案、给药和毒性也是需要考虑的重要因素。
关键数值与推荐
- 抗PD-1单药和BRAF/MEK抑制剂目前被认为是已切除III期黑色素瘤的标准治疗。
- 推荐IIIB-IIID期(AJCCv8)黑色素瘤患者接受辅助治疗,IIIA期患者可考虑辅助治疗。
- 已切除IV期黑色素瘤中纳武利尤单抗是唯一获批药物。
临床怎么用
- IIIB-IIID期(AJCCv8)黑色素瘤术后推荐辅助治疗,IIIA期可考虑辅助治疗。
- 辅助治疗选择需综合考虑方案、给药方式和毒性。
- 已切除IV期黑色素瘤可选用纳武利尤单抗,双免疫联合为潜在选择但需长期数据。
局限性
- 确定哪种治疗对总生存影响最大需要长期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with resected stage III and IV melanoma have a high risk of recurrence. As the outcomes for patients with metastatic disease have improved dramatically over the past decade due to systemic therapy, more recently so too have the outcomes of patients with resected stage III and IV melanoma with the introduction of checkpoint inhibitor immunotherapy and targeted therapy in the adjuvant setting. MATERIALS AND METHODS: This review outlines the latest clinical trial data, the current adjuvant treatment landscape and its application to clinical practice and expected future progress for the management of early-stage melanoma. RESULTS: Anti-programmed cell death protein 1 monotherapy and BRAF/MEK inhibitors are currently deemed standard of care for resected stage III melanoma. For patients with stage IIIB [American Joint Committee on Cancer staging system version 7 (AJCCv7)] melanoma, 2-year and 3-year recurrence-free survival is approximately 72% and 65% for nivolumab, 70% and 65.7% for pembrolizumab and 68% and 60% for dabrafenib/trametinib, respectively. For stage IIIC (AJCCv7) melanoma, 2-year and 3-year recurrence-free survival is 60% and 53.5% for nivolumab, 60% and 54.3% for pembrolizumab and 59% and 47% for dabrafenib/trametinib, respectively. Adjuvant treatment is recommended for patients with stage IIIB-IIID [AJCC staging system version 8 (AJCCv8)] melanoma, and may be considered for patients with stage IIIA melanoma. For resected stage IV, nivolumab is the only approved agent; however, recent results from a phase II clinical trial show promising efficacy for combined ipilimumab and nivolumab as well. Long-term data are required to determine which therapy has the greatest impact on overall survival. Schedules, delivery and toxicity are also important factors to consider when selecting adjuvant treatment. CONCLUSIONS: Randomized studies of patients with resected high-risk melanoma have shown that immunotherapy or targeted therapy improve recurrence-free survival compared with placebo/ipilimumab. In order to optimize these treatments, prognostic and predictive biomarkers, as well as strategies to reduce treatment-related toxicities and overcome resistance, are required.
引用
- Dimitriou F, Long GV, Menzies AM, et al. Novel adjuvant options for cutaneous melanoma. Ann Oncol. 2021. PMID: 33771664. doi:10.1016/j.annonc.2021.03.198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。